Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Evome Medical Technologies Inc V.EVMT

Alternate Symbol(s):  LNDZF

Evome Medical Technologies Inc. is an international medical device company, which is focused on human performance and rehabilitative solutions. The Company’s products include Biodex Rehab product, Damar Plastics product, Mio-Guard product, Simbex services, and SDP product. Its Biodex Rehab products include Isokinetic Systems, Gait Trainer, Body-Weight Supported Training, Cycles and Ergometers, and Squat-Assist Trainer. Its Mio-Guard products include bags, cases and kits, braces, and supports, diagnostics and instruments, furniture, and equipment, padding and splinting, personal protection, sanitizers and disinfectants, and tapes and wraps. Its applications include fall risk screening and conditioning, patient-driven payment model (PDPM), wellness, sports medicine solutions, neurological involvement, safe patient handling and mobility, and senior living and rehabilitation. It offers concussion, fall screening and balance assessment and training programs.


TSXV:EVMT - Post by User

Comment by TheRock07on Aug 07, 2016 5:16pm
168 Views
Post# 25118002

RE:RE:RE:Could Easily Raise Dividend

RE:RE:RE:Could Easily Raise DividendYour first point is correct.
They have access to a LOC should business growth demand its use.

As it is, adding $10 million in cash to current loan receivables is quite a solid growth rate which will internally fund continueing growth through excess cash flows.

And, I must admit, your second point is also correct.

Using their excess cash to fund more loan receivables will not significantly increase operating expenses and certainly not 60 % as  I mistakenly used.

So my estimate of operating earnings if excess cash is used to grow the loan portfolio is not correct.

Your estimate of $3 million would be much closer to the truth.

Which makes this investment all that better..
Bullboard Posts